Opinion|Videos|April 17, 2025
Applying Learnings From the SPECTREM Study to Clinical Practice
Panelists discuss how the SPECTREM study (Stein Gold, 2024) demonstrated guselkumab’s remarkable efficacy for moderate psoriasis in high-impact areas, with 74% of treated patients achieving clear/almost clear skin (Investigator’s Global Assessment [IGA] 0/1) at week 16 compared with just 12% on placebo, while importantly showing consistent effectiveness regardless of baseline body surface area (BSA)—suggesting that BSA alone shouldn’t determine treatment approach and validating biologic therapy for patients with limited but highly impactful disease.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What were some of the key findings of the SPECTREM study? (
Stein Gold, 2024 )- 74% of patients on guselkumab achieved the primary end point of IGA 0/1 at week 16 compared with placebo (12%).
Over 70% of patients were able to achieve the primary end point regardless of baseline BSA.
Advertisement
Related to this article
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.
Autumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.
Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.
Advertisement
Advertisement
Trending on HCPLive
1
Zabopegdutide Improves Fibrosis, MASH Resolution at 48 Weeks
2
Asundexian Receives FDA Approval for Secondary Stroke Prevention
3
RNA Editing With WVE-006 Restores Functional AAT, Cuts Z-AAT in AATD
4
Efinopegdutide Improves MASH Resolution, Fibrosis in Phase 2b Trial
5